Recent advances on structural modifications of benzothiazoles and their conjugate systems as potential chemotherapeutics

Expert Opinion on Investigational Drugs

Volumn 21, Issue 5, 2012, Pages 619-635

  Ahmed, Kamal ^a   Yellamelli Valli Venkata, Srikanth ^a   Mohammed, Naseer Ahmed Khan ^a   Sultana, Farheen ^a   Methuku, Kashi Reddy ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Antitumor activity; Aryl hydrocarbon receptor; Benzothiazoles; Chemotherapeutic agents; DNA adduct; Pharmacokinetics; Phortress

Indexed keywords

2 (4 AMINO 3 METHYLPHENYL)BENZOTHIAZOLE; 2 (4 AMINOPHENYL) 6 (IMIDAZOLIN 2 YL)BENZOTHIAZOLE; 4 (BENZOTHIAZOL 2 YL) 4 HYDROXY 2,5 CYCLOHEXADIEN 1 ONE; 5 FLUORO 2 (4 LYSYLAMINO 3 METHYLPHENYL)BENZOTHIAZOLE; 5F 203; ANTINEOPLASTIC AGENT; BENZOTHIADIAZINE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; CJM 126; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GW 610; HETEROCYCLIC COMPOUND; MITOXANTRONE; PMX 464; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; RXF 944XL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CHEMICAL MODIFICATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS;

EID: 84859729348     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.676043     Document Type: Review

References (97)

1. Lagunin A, Stepanchikova A, Filimonov D, Poroikov V. PASS: prediction of activity spectra for biologically active substances. Bioinformatics 2000;16:747-8
2. Nogradi A, Vrbova G. The effect of riluzole treatment in rats on the survival of injured adult and grafted embryonic motoneurons. Eur J Neurosci 2001;13:113-18 (Pubitemid 32055870)
3. Bae HJ, Lee YS, Kang DW, et al. Neuroprotective effect of low dose riluzole in gerbil model of transient global ischemia. Neurosci Lett 2000;294:29-32
4. Benavides J, Camelin JC, Mitrani N, et al. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission-II. Biochemical properties. Neuropharmacology 1985;24:1085-92 (Pubitemid 16176969)
5. Amnerkar ND, Bhusari KP. Synthesis, anticonvulsant activity and 3D-QSAR study of some prop-2-eneamido and 1-acetyl-pyrazolin derivatives of aminobenzothiazole. Eur J Med Chem 2010;45:149-59
6. Deng XQ, Song MX, Wei CX, et al. Synthesis and anticonvulsant activity of 7-alkoxy-triazolo-[3, 4-b]benzo[d] thiazoles. Med Chem 2010;6:313-20
7. Siddiqui N, Ahsan W. Benzothiazole incorporated barbituric acid derivatives: synthesis and anticonvulsant screening. Arch Pharm (Weinheim) 2009;342:462-8
8. Chopade RS, Bahekar RH, Khedekar PB, et al. Synthesis and anticonvulsant activity of 3-(6-substituted-benzothiazol-2-yl)-6-phenyl-[1,3]-xazinane-2- thiones. Arch Pharm (Weinheim) 2002;335:381-8
9. Jimonet P, Audiau F, Barreau M, et al. Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J Med Chem 1999;42:2828-43 (Pubitemid 29370427)
10. Burger A, Sawhey SN. Antimalarials. 3. Benzothiazole amino alcohols. J Med Chem 1968;11:270-3
11. Hori N, Tsukamoto G, Imamura A, et al. Novel disease-modifying antirheumatic drugs. I. Synthesis and antiarthritic activity of 2-(4-methylphenyl)benzothiazoles. Chem Pharm Bull (Tokyo) 1992;40:2387-90
12. Palmer PJ, Trigg RB, Warrington JV. Benzothiazolines as antituberculous agents. J Med Chem 1971;14:248-51
13. Huang Q, Mao J, Wan B, et al. Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles. J Med Chem 2009;52:6757-67
14. Waisser K, Dolezal M, Sidoova E, et al. Biological side-effects of potential anti-tubercular agents. XIV. Relation between the chemical structure, antitubercular activity and hepatotoxicity of 2-alkylthio-6-(2-chlorobenzamido) benzothiazoles. Ceska Farm 1988;37:437-9 (Pubitemid 19013934)
15. Patel NB, Khan IH, Rajani SD. Antimycobacterial and antimicrobial study of new 1,2,4-triazoles with benzothiazoles. Arch Pharm (Weinheim) 2010;343:692-9
16. Lee YR, Jin GH, Lee SM, et al. Inhibition of TNF-alpha-mediated inflammatory responses by a benzodioxolylacetylamino-linked benzothiazole analog in human fibroblast-like synoviocytes. Biochem Biophys Res Commun 2011;408:625-9
17. Jin GH, Li H, An S, et al. Design, synthesis and activity of benzothiazole-based inhibitors of NO production in LPS-activated macrophages. Bioorg Med Chem Lett 2010;20:6199-02
18. Paramashivappa R, Phani Kumar P, Subba Rao PV, Srinivasa Rao A. Design, synthesis and biological evaluation of benzimidazole/benzothiazole and benzoxazole derivatives as cyclooxygenase inhibitors. Bioorg Med Chem Lett 2003;13:657-60 (Pubitemid 36298462)
19. Al-Tel TH, Al-Qawasmeh RA, Zaarour R. Design, synthesis and in vitro antimicrobial evaluation of novel Imidazo [1,2-a]pyridine and imidazo[2,1-b][1,3] benzothiazole motifs. Eur J Med Chem 2011;46:1874-81
20. Stella A, Segers K, De Jonghe S, et al. Synthesis and antibacterial evaluation of a novel series of 2-(1,2-dihydro-3-oxo-3H-pyrazol-2-yl) benzothiazoles. Chem Biodivers 2011;8:253-65
21. Nam NH, Dung PT, Thuong PT. Synthesis and biological evaluation of a series of 2-(substitutedphenyl) benzothiazoles. Med Chem 2011;7:127-34
22. Gilani SJ, Khan SA, Siddiqui N, et al. Synthesis and in vitro antimicrobial activity of novel N-(6-chlorobenzo[d] thiazol-2-yl) hydrazine carboxamide derivatives of benzothiazole class. J Enzyme Inhib Med Chem 2011;26:332-40
23. Franchini C, Muraglia M, Corbo F, et al. Synthesis and biological evaluation of 2-mercapto-1,3-benzothiazole derivatives with potential antimicrobial activity. Arch Pharm (Weinheim) 2009;342:605-13
24. Latrofa A, Franco M, Lopedota A, et al. Structural modifications and antimicrobial activity of N-cycloalkenyl-2-acylalkylidene-2,3-dihydro-1,3- benzothiazoles. Farmaco 2005;60:291-7 (Pubitemid 40545944)
25. Youssef AM, Noaman E. Synthesis and evaluation of some novel benzothiazole derivatives as potential anticancer and antimicrobial agents. Arzneimittelforschung 2007;57:547-53 (Pubitemid 47435278)
26. Singh T, Srivastava VK, Saxena KK, et al. Synthesis of new thiazolyl thiazolidinylbenzothiazoles and thiazolylazetidinylbenzothiazoles as potential insecticidal, antifungal, and antibacterial agents. Arch Pharm (Weinheim) 2006;339:466-72 (Pubitemid 44320227)
27. Gagos M, Menestrina G, Niewiadomy A, Gruszecki WI. Molecular organization of the antifungal and anticancer drug 2-(2,4-dihydroxyphenylo)-5,6- dichlorobenzothiazole in solution and in monolayers: an effect of pH. J Photochem. Photobiol B 2005;80:101-6 (Pubitemid 40984408)
28. Chohan ZH, Scozzafava A, Supuran CT. Zinc complexes of benzothiazole-derived Schiff bases with antibacterial activity. J Enzyme Inhib Med Chem 2003;18:259-63 (Pubitemid 36827038)
29. Bujdakova H, Kuchta T, Sidoova E, Gvozdjakova A. Anti-Candida activity of four antifungal benzothiazoles. FEMS Microbiol Lett 1993;112:329-33
30. Havrylyuk D, Mosula L, Zimenkovsky B, et al. Synthesis and anticancer activity evaluation of 4-thiazolidinones containing benzothiazole moiety. Eur J Med Chem 2010;45:5012-21
31. Kamal A, Srikanth YVV, Khan MNA, et al. 2-Anilinonicotinyl linked 2-aminobenzothiazoles and [1,2,4] triazolo[1,5-b] [1,2,4]benzothiadiazine conjugates as potential mitochondrial apoptotic inducers. Bioorg Med Chem 2011;23:7136-50
32. Trapani G, Franco M, Latrofa A, et al. Synthesis, in vitro and in vivo cytotoxicity, and prediction of the intestinal absorption of substituted 2-ethoxycarbonyl-imidazo[2,1-b] benzothiazoles. Eur J Pharm Sci 2001;14:209-16 (Pubitemid 32884317)
33. Amino N, Ideyama Y, Yamano M, et al. YM-201627: an orally active antitumour agent with selective inhibition of vascular endothelial cell proliferation. Cancer Lett 2006;238:119-27 (Pubitemid 43851149)
34. Kumbhare RM, Kumar KV, Ramaiah MJ, et al. Synthesis and biological evaluation of novel Mannich bases of 2-arylimidazo[2,1-b] benzothiazoles as potential anti-cancer agents. Eur J Med Chem 2011;46:4258-66
35. Huang S, Liu Z, Tian SS, et al. Discovery of 2-amino-6- carboxamidobenzothiazoles as potent Lck inhibitors. Bioorg Med Chem Lett 2008;18:2324-8 (Pubitemid 351442906)
36. Khokra SL, Arora K, Mehta H, et al. Common methods to synthesize benzothiazole derivatives and their medicinal significance: a review. Int J Curr Pharm Res 2011;2:1356-77
37. Chaudhary P, Sharma PK, Sharma A, Varshney J. Recent advances in pharmacological activity of benzothiazole derivatives. Int J Curr Pharm Res 2010;2:5-11
38. Sanap MS, Dighe NS, Pattan SR, et al. Benzothiazole it's current pharmacological profile and methods of synthesis. Pharmacology Online 2010;1:238-44
39. Priyanka Sharma NK, Jha KK. Benzothiazole: the molecule of diverse biological activities. Int J Curr Pharm Res 2010;2:1-6
40. Yadav PS, Devprakash Senthilkumar GP. Benzothiazole: different methods of synthesis and diverse biological activities. Int J Pharm Sci Drug Res 2011;3:1-7
41. Caleta I, Kralj M, Branimir BB, et al. Novel cyano-and amidinobenzothiazole derivatives: synthesis, antitumour evaluation, and X-ray and quantitative structure-activity relationship (QSAR) analysis. J Med Chem 2009;52:1744-56
42. Yates PC, Mccall CJ, Stevens MFG. Structural Studies on Benxothiazoles. Crystal and molecular structure of 5,6-dimethoxy-Z-(4-methoxyphenyl)- benzothiazole and molecular orbital calculations on related compounds. Tetrahedron 1991;47:6493-02
43. Stevens MF, McCall CJ, Lelieveld P, et al. Structural studies on bioactive compounds. 23. Synthesis of polyhydroxylated 2-phenylbenzothiazoles and a comparison of their cytotoxicities and pharmacological properties with genistein and quercetin. J Med Chem 1994;37:1689-95 (Pubitemid 24195484)
44. Shi DF, Bradshaw TD, Wrigley S, et al. Antitumour benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. J Med Chem 1996;39:3375-84 (Pubitemid 26322863)
45. Bradshaw TD, Shi DF, Schultz RJ, et al. Influence of 2-(4-aminophenyl) benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo. Br J Cancer 1998;78:421-9 (Pubitemid 28360627)
46. Bradshaw TD, Stevens MF, Westwell AD. The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds. Curr Med Chem 2001;8:203-10 (Pubitemid 32409772)
47. Brantley E, Trapani V, Alley MC, et al. Fluorinated 2-(4-amino-3- methylphenyl) benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells. Drug Metab Dispos 2004;32:1392-01 (Pubitemid 39564559)
48. O'Brien SE, Browne HL, Bradshaw TD, et al. Antitumour benzothiazoles. Frontier molecular orbital analysis predicts bioactivation of 2-(4-aminophenyl)benzothiazoles to reactive intermediates by cytochrome P4501A1. Org Biomol Chem 2003;1:493-7.
49. Chua MS, Shi DF, Wrigley S, et al. Antitumour benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl)benzothiazoles and investigations into the role of acetylation in the antitumour activities of the parent amines. J Med Chem 1999;42:381-92 (Pubitemid 29085098)
50. Kashiyama E, Hutchinson I, Chua M-S, et al. J Med Chem 1999;42:4172-84
51. Shi DF, Bradshaw TD, Chua MS, et al. Antitumour benzothiazoles. Part 15: the synthesis and physico-chemical properties of 2-(4-aminophenyl)benzothiazole sulfamate salt derivatives. Bioorg Med Chem Lett 2001;11:1093-5 (Pubitemid 32319989)
52. Hutchinson I, Chua MS, Browne HL, et al. Antitumour benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl) benzothiazoles. J Med Chem 2001;44:1446-55 (Pubitemid 32852121)
53. Trapani V, Patel V, Leong CO, et al. DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. Br J Cancer 2003;88:599-05 (Pubitemid 36363371)
54. Bradshaw TD, Bibby MC, Double JA, et al. Preclinical evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Cancer Ther 2002;1:239-46.
55. Hutchinson I, Jennings SA, Vishnuvajjala BR, et al. Antitumour benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumour 2-(4-aminophenyl)benzothiazole amino acid prodrugs. J Med Chem 2002;45:744-7 (Pubitemid 34145721)
56. Bradshaw TD, Westwell AD. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate. Curr Med Chem 2004;11:1009-21 (Pubitemid 38428650)
57. Bradshaw TD, Chua MS, Browne HL, et al. In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Br J Cancer 2002;86:1348-54
58. Mukherjee A, Martin SG. In vitro cytotoxicity of Phortress against colorectal cancer. Int J Oncol 2006;29:1287-94
59. Hutchinson I, Bradshaw TD, Matthews CS, et al. Antitumour benzothiazoles. Part 20: 3'-cyano and 3'-alkynyl-substituted 2-(4'-aminophenyl) benzothiazoles as new potent and selective analogues. Bioorg Med Chem Lett 2003;13:471-4 (Pubitemid 36259716)
60. Choi SJ, Park HJ, Lee SK, et al. Solid phase combinatorial synthesis of benzothiazoles and evaluation of topoisomerase II inhibitory activity. Bioorg Med Chem 2006;14:1229-35 (Pubitemid 43059816)
61. Gong B, Hong F, Kohm C, et al. Synthesis and SAR of 2-arylbenzoxazoles, benzothiazoles and benzimidazoles as inhibitors of lysophosphatidic acid acyltransferase-beta. Bioorg Med Chem Lett 2004;14:1455-9 (Pubitemid 38299428)
62. Racane L, Kralj M, Suman L, et al. Novel amidino substituted 2-phenylbenzothiazoles: synthesis, antitumour evaluation in vitro and acute toxicity testing in vivo. Bioorg Med Chem 2010;18:1038-44
63. Devmurari VP, Shivanand P, Jivani NP, et al. Synthesis and anticancer activity of some novel2-substituted benzothiazole derivatives. Int J Chem Tech Res 2010;2:681-9
64. Bhuva HA, Parmar RR, Kini SG. Synthesis and cytotoxic activity of some novel substituted 2-phenyl-1,3-benzothiazoles. J Pharm Res 2010;3:980-3
65. Prabhu PP, Shastry CS, Pande S, Pai A. Synthesis,characterization and biological evaluation of novel aryl benzothiazole derivatives. J Pharm Res 2011;4:2209-11
66. Hu WP, Chen YK, Liao CC, et al. Synthesis, and biological evaluation of 2-(4-aminophenyl)benzothiazole derivatives as photosensitizing agents. Bioorg Med Chem 2010;18:6197-07
67. Tzanopoulou S, Sagnou M, Paravatou-Petsotas M, et al. Evaluation of Re and (99m)Tc complexes of 2-(4'-aminophenyl)benzothiazole as potential breast cancer radio pharmaceuticals. J Med Chem 2010;53:4633-41
68. Tzanopoulou S, Pirmettis IC, Patsis G, et al. Synthesis, characterization, and biological evaluation of M(I)(CO)3 (NNO) complexes (M = Re, 99mTc) conjugated to 2-(4-amino phenyl) benzothiazole as potential breast cancer radiopharmaceuticals. J Med Chem 2006;49:5408-10 (Pubitemid 44373173)
69. Mortimer CG, Wells G, Crochard JP, et al. Antitumour benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines. J Med Chem 2006;49:179-85 (Pubitemid 43077331)
70. Aiello S, Wells G, Stone EL, et al. Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). J Med Chem 2008;51:5135-9
71. Wells G, Bradshaw TD, Diana P, et al. Antitumour benzothiazoles. Part 10: the synthesis and antitumour activity of benzothiazole substituted quinol derivatives. Bioorg Med Chem Lett 2000;10:513-15 (Pubitemid 30153625)
72. Wells G, Berry JM, Bradshaw TD, et al. 4-Substituted 4-hydroxycyclohexa- 2, 5-dien-1-ones with selective activities against colon and renal cancer cell lines. J Med Chem 2003;46:532-41 (Pubitemid 36182755)
73. Lion CJ, Matthews CS, Wells G, et al. Antitumour properties of fluorinated benzothiazole-substituted hydroxycyclohexa-2,5-dienones ('quinols'). Bioorg Med Chem Lett 2006;16:5005-8 (Pubitemid 44255890)
74. Huang ST, Hsei IJ, Chen C. Synthesis and anticancer evaluation of bis (benzimidazoles), bis(benzoxazoles), and benzothiazoles. Bioorg Med Chem 2006;14:6106-19 (Pubitemid 44080573)
75. Viegas-Junior C, Danuello A, da Silva Bolzani V, et al. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 2007;14(17):1829-52 (Pubitemid 47163402)
76. Xie L, Zhai X, Ren L, et al. Design, synthesis and antitumor activity of novel artemisinin derivatives using hybrid approach. Chem Pharm Bull (Tokyo) 2011;59:984-90
77. Decker M. Hybrid molecules incorporating natural products: applications in cancer therapy, neurodegenerative disorders and beyond. Curr Med Chem 2011;18:1464-75
78. Breen EC, Walsh JJ. Tubulin-targeting agents in hybrid drugs. Curr Med Chem 2010;17:609-39
79. Mehta G, Singh V. Hybrid systems through natural product leads: an approach towards new molecular entities. Chem Soc Rev 2002;31:324-34
80. Kamal A, Reddy KS, Khan MN, et al. Synthesis, DNA-binding ability and anticancer activity of benzothiazole/benzoxazole-pyrrolo[2,1-c][1,4] benzodiazepine conjugates. Bioorg Med Chem 2010;18:4747-61
81. Kamal A, Khan MN, Reddy KS, et al. Synthesis, structural characterization and biological evaluation of novel [1,2,4] triazolo[1,5-b][1,2,4] benzothiadiazinebenzothiazole conjugates as potential anticancer agents. Chem Biol Drug Des 2008;71:78-86
82. Kamal A, Kumar BA, Suresh P, et al. An efficient one-pot synthesis of benzothiazolo-4beta-anilinopodophyllotoxin congeners: DNA topoisomerase-II inhibition and anticancer activity. Bioorg Med Chem Lett 2011;21:350-3
83. Tasler S, Muller O, Wieber T, et al. N-substituted 2'-(aminoaryl) benzothiazoles as kinase inhibitors: hit identification and scaffold hopping. Bioorg Med Chem Lett 2009;19:1349-56
84. Tasler S, Muller O, Wieber T, et al. Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimization. Bioorg Med Chem 2009;17:6728-37
85. Bradshaw TD, Wrigley S, Shi DF, et al. 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity. Br J Cancer 1998;77:745-52 (Pubitemid 28077462)
86. Stanley LA, Coroneos E, Cuff R, et al. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J Histochem Cytochem 1996;44:1059-67 (Pubitemid 26293378)
87. Loaiza-Perez AI, Trapani V, Hose C, et al. Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumour agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol Pharmacol 2002;61:13-19 (Pubitemid 34049507)
88. Hose CD, Hollingshead M, Sausville EA, Monks A. Induction of CYP1A1 in tumour cells by the antitumour agent 2-[4-amino-3-methylphenyl]-5-fluoro- benzothiazole: a potential surrogate marker for patient sensitivity. Mol Cancer Ther 2003;2:1265-72
89. Chua MS, Kashiyama E, Bradshaw TD, et al. Role of Cyp1A1 in modulation of antitumour properties of the novel agent 2-(4-amino-3-methylphenyl) benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 2000;60:5196-03
90. Bradshaw TD, Trapani V, Vasselin DA, Westwell AD. The aryl hydrocarbon receptor in anticancer drug discovery: friend or foe? Curr Pharm Des 2002;8:2475-90 (Pubitemid 35331533)
91. Whitlock JP Jr. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 1999;39:103-25 (Pubitemid 29222553)
92. Hose C, Riviera M, Sausville E, Monks A. Induction of cytochrome P450 CYP1A1 and cytochrome P450 CYP1B1 by 2-(4-amino-3-methylphenyl)benzothiazole (BZ) in 60 human tumour cell lines: correlation with BZ toxicity. Proc Am Assoc Cancer Res 2001;42(2749):511
93. Tan BS, Tiong KH, Muruhadas A, et al. CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells. Mol Cancer Ther 2011;10:1982-92
94. Leong CO, Gaskell M, Martin EA, Heydon RT. Antitumour 2-(4-aminophenyl) benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Br J Cancer 2003;88:470-7 (Pubitemid 36308161)
95. Leong CO, Suggitt M, Swaine DJ, et al. In vitro, in vivo, and in silico analyses of the antitumour activity of 2-(4-amino-3-methylphenyl)-5- fluorobenzothiazoles. Mol Cancer Ther 2004;3:1565-75 (Pubitemid 40136712)
96. Brantley E, Antony S, Kohlhagen G, et al. Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells. Cancer Chemother Pharmacol 2006;58:62-72
97. Novak M, Chakraborty M. Reactions of a putative metabolite of the model antitumor drug 2-(4-aminophenyl) benzothiazole with purines and pyrimidines. J Phys Org Chem 2011;24:960-8